Cannabidiol for psychotic disorders

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 2 registered trials.

Why this status

  1. 16 Jan 2025: Trial registered, NCT06778564
  2. 5 Oct 2026: Trial started, NCT06778564

The trials

NCT06778564: Stratification and Treatment in Early Psychosis Study - ENHANCE

State
Under way
Phase
Phase 3
People
250 planned
Started
5 Oct 2026
Primary completion
Feb 2028
Arms
Cannabidiol (CBD)
Results
None posted
  1. 16 Jan 2025: Trial registered
  2. 5 Oct 2026: Trial started

NCT07326124: Stratification and Treatment in Early Psychosis Study -ASSIST

State
Not started
Phase
Phase 3
People
250 planned
Started
Jan 2027
Primary completion
Sep 2028
Arms
Experimental: Cannobidiol
Results
None posted
  1. 8 Jan 2026: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Also known as Cardiolrx, Canapure PH, Cannabidiol (Epidiolex), Cannabidiol Oral Solution, Epidiolex, Epidiolex 100 mg/mL Oral Solution, Epidyolex, GWP42003-P 10 mg/kg/day Dose, GWP42003-P 20 mg/kg/day Dose, GWP42003-P 5 mg/kg/day Dose, MediCabilis.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.